Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer?

References

• Ataman F, Poortmans P, Davis J B, Bernier J, Giraud J Y, Kouloulias V E, Pierart M, Bolla M. High conformality radiotherapy in Europe: Thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991. European Journal of Cancer 2004; 40: 2411–2416
   PubMed Web of Science ®Google Scholar
• Baum C, Birkner M, Alber M, Paulsen F, Nüsslin F. Dosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer. Radiotherapy and Oncology 2005; 76: 35–42
   PubMed Web of Science ®Google Scholar
• Baum C, Alber M, Birkner M, Nüsslin F. Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiotherapy and Oncology 2006; 78: 27–35
   PubMed Web of Science ®Google Scholar
• Beyersdorff D, Hamm B. MRI for troubleshooting detection of prostate cancer. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2005; 177: 788–795
   Google Scholar
• Beyersdorff D, Darsow U, Stephan C, Schnorr D, Loening S, Taupitz M. MRI of prostate cancer using three different coil systems: Image quality, tumor detection, and staging. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2003; 175: 799–805
   Google Scholar
• Boehmer D, Maingon P, Poortmans P, Baron M H, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M, EORTC radiation oncology group. Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology 2006; 79: 259–269
   PubMed Web of Science ®Google Scholar
• Bos L J, van der Geer J, van Herk M, Mijnheer B J, Lebesque J V, Damen E M. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT. Radiotherapy and Oncology 2005; 76: 18–26
   PubMed Web of Science ®Google Scholar
• Breeuwsma A J, Pruim J, Jongen M M, Suurmeijer A J, Vaalburg W, Nijman R J, de Jong I J. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32: 668–673
   PubMed Web of Science ®Google Scholar
• Claus F G, Hricak H, Hattery R R. Pretreatment evaluation of prostate cancer: Role of MR imaging and 1H MR spectroscopy. Radiographics 2004; 24: S167–180
   PubMed Web of Science ®Google Scholar
• de Crevoisier R, Tucker S L, Dong L, Mohan R, Cheung R, Cox J D, Kuban D A. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics 2005; 62: 965–973
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, De Neve W. The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiotherapy and Oncology 2005; 75: 325–333
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N, Ost P, Vandecasteele K, De Neve W. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiotherapy and Oncology 2008; 89: 205–213
   PubMed Web of Science ®Google Scholar
• Dhingsa R, Qayyum A, Coakley F V, Lu Y, Jones K D, Swanson M G, Carroll P R, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: Effect of clinical data on reader accuracy. Radiology 2004; 230: 215–220
   PubMed Web of Science ®Google Scholar
• Engelbrecht M R, Jager G J, Laheij R J, Verbeek A L, van Lier H J, Barentsz J O. Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. European Radiology 2002; 12: 2294–2302
   PubMed Web of Science ®Google Scholar
• Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S. Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine 2005; 46: 1642–1649
   PubMed Web of Science ®Google Scholar
• Fischer B M, Olsen M W, Ley C D, Klausen T L, Mortensen J, Højgaard L, Kristjansen P E. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. European Joural of Nuclear Medicine and Molecular Imaging 2006; 33: 697–702
   PubMed Web of Science ®Google Scholar
• Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiologica 2008; 49: 107–120
   PubMed Web of Science ®Google Scholar
• Fütterer J J, Heijmink S W, Scheenen T W, Veltman J, Huisman H J, Vos P, Hulsbergen-Van de Kaa C A, Witjes J A, Krabbe P F, Heerschap A, Barentsz J O. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449–458
   PubMed Web of Science ®Google Scholar
• Fütterer J J, Engelbrecht M R, Huisman H J, Jager G J, Hulsbergen-van De Kaa C A, Witjes J A, Barentsz J O. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: Experienced versus less experienced readers. Radiology 2005; 237: 541–549
   PubMed Web of Science ®Google Scholar
• Fütterer J J, Scheenen T W, Huisman H J, Klomp D W, van Dorsten F A, Hulsbergen-van de Kaa C A, Witjes J A, Heerschap A, Barentsz J O. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Investigative Radiology 2004; 39: 671–680
   PubMed Web of Science ®Google Scholar
• Galalae R M, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. International Journal Radiation Oncology Biology Physics 2004; 58: 1048–1055
   PubMed Web of Science ®Google Scholar
• Glunde K, Ackerstaff E, Mori N, Jacobs M A, Bhujwalla Z M. Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions. Molecular Pharmaceutics 2006; 3: 496–506
   PubMed Web of Science ®Google Scholar
• Grosu A L, Piert M, Weber W A, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann F B, Schwaiger M, Molls M. Positron emission tomography for radiation treatment planning. Strahlentherapie und Onkologie 2005; 181: 483–499
   PubMed Web of Science ®Google Scholar
• Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 140–147
   PubMed Web of Science ®Google Scholar
• Hanley J A, McNeil B J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36
   PubMed Web of Science ®Google Scholar
• Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. British Journal of Radiology 2005; 78: S103–111
   PubMed Web of Science ®Google Scholar
• Hricak H, Choyke P L, Eberhardt S C, Leibel S A, Scardino P T. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007; 243: 28–53
   PubMed Web of Science ®Google Scholar
• Huisman H J, Fütterer J J, van Lin E N, Welmers A, Scheenen T W, van Dalen J A, Visser A G, Witjes J A, Barentsz J O. Prostate cancer: Precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology 2005; 236: 311–317
   PubMed Web of Science ®Google Scholar
• Jacob R, Hanlon A L, Horwitz E M, Movsas B, Uzzo R G, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100: 538–543
   PubMed Web of Science ®Google Scholar
• Jacob R, Hanlon A L, Horwitz E M, Movsas B, Uzzo R G, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal ofRadiation Oncology Biology Physics 2005; 61: 695–701
   PubMed Web of Science ®Google Scholar
• Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel M S, Trojan L, Ederle J, Abel U, Kauczor H U, Semmler W, Delorme S. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. European Radiology 2004; 14: 1793–1801
   PubMed Web of Science ®Google Scholar
• Kim J K, Hong S S, Choi Y J, Park S H, Ahn H, Kim C S, Cho K S. Wash-in rate on the basis of dynamic contrast-enhanced MRI: Usefulness for prostate cancer detection and localization. Journal of Magnetic Resonance Imaging 2005; 22: 639–646
   PubMed Web of Science ®Google Scholar
• Kotzerke J, Volkmer B G, Glatting G, van den Hoff J, Gschwend J E, Messer P, Reske S N, Neumaier B. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25–30
   PubMedGoogle Scholar
• Kupelian P A, Potters L, Khuntia D, Ciezki J P, Reddy C A, Reuther A M, Carlson T P, Klein E A. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. International Journal of Radiation Oncology Biology Physics 2004; 58: 25–33
   PubMed Web of Science ®Google Scholar
• Kurhanewicz J, Vigneron D B, Hricak H, Narayan P, Carroll P, Nelson S J. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 1996; 198: 795–805
   PubMed Web of Science ®Google Scholar
• Martin T, Baltas D, Kurek R, Röddiger S, Kontova M, Anagnostopoulos G, Dannenberg T, Buhleier T, Skazikis G, Tunn U, Zamboglou N. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlentherapie und Onkologie 2004; 180: 225–232
   PubMed Web of Science ®Google Scholar
• Mazaheri Y, Shukla-Dave A, Hricak H, Fine S W, Zhang J, Inurrigarro G, Moskowitz C S, Ishill N M, Reuter V E, Touijer K, Zakian K L, Koutcher J A. Prostate cancer: Identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging – correlation with pathologic findings. Radiology 2008; 246: 480–488
   PubMed Web of Science ®Google Scholar
• Mock U, Bogner J, Georg D, Auberger T, Pötter R. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlentherapie und Onkologie 2005; 181: 448–455
   PubMed Web of Science ®Google Scholar
• Morgan P B, Hanlon A L, Horwitz E M, Buyyounouski M K, Uzzo R G, Pollack A. Radiation dose and late failures in prostate cancer. International Journal of Radiation Oncology Biology Physics 2007; 67: 1074–1081
   PubMed Web of Science ®Google Scholar
• Nestle U, Kremp S, Grosu A L. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives. Radiotherapy and Oncology 2006; 81: 209–225
   PubMed Web of Science ®Google Scholar
• Northwood I C, Tong A H, Crawford B, Drobnies A E, Cornell R B. Shuttling of CTP:Phosphocholine cytidylyltransferase between the nucleus and endoplasmic reticulum accompanies the wave of phosphatidylcholine synthesis during the G(0)– > G(1) transition. The Journal of Biological Chemistry 1999; 274: 26240–26248
   PubMed Web of Science ®Google Scholar
• Okamura T, Umemoto Y, Yamashita K, Suzuki S, Shirai T, Hashimoto Y, Kohri K. Pitfalls with MRI evaluation of prostate cancer detection: Comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens. Urologia Internationalis 2006; 77: 301–306
   PubMed Web of Science ®Google Scholar
• Pellizzon A C, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. International Journal of Medical Sciences 2008; 5: 113–120
   PubMedGoogle Scholar
• Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh A C, Scrase C, Van Poppel H, Bolla M, EORTC Radiation Oncology Group. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiotherapy and Oncology 2007; 84: 121–127
   PubMed Web of Science ®Google Scholar
• Reske S N, Blumstein N M, Neumaier B, Gottfried H W, Finsterbusch F, Kocot D, Möller P, Glatting G, Perner S. Imaging prostate cancer with 11C-choline PET/CT. Journal of Nuclear Medicine 2006; 47: 1249–1254
   PubMed Web of Science ®Google Scholar
• Sala E, Eberhardt S C, Akin O, Moskowitz C S, Onyebuchi C N, Kuroiwa K, Ishill N, Zelefsky M J, Eastham J A, Hricak H. Endorectal MR imaging before salvage prostatectomy: Tumor localization and staging. Radiology 2006; 238: 176–183
   PubMed Web of Science ®Google Scholar
• Schaefer A, Kremp S, Hellwig D, Rübe C, Kirsch C M, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: Derivation from phantom measurements and validation in patient data. European Journal of Nuclear Medicine and Molecular Imaging 2008; 35: 1989–1999
   PubMed Web of Science ®Google Scholar
• Schlemmer H P, Merkle J, Grobholz R, Jaeger T, Michel M S, Werner A, Rabe J, van Kaick G. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens. European Radiology 2004; 14: 309–317
   PubMed Web of Science ®Google Scholar
• Schmuecking M, Mentzel H J, Bloch B N, Scheithauer M, Schilling B, Salz H, Kaiser W A, Wendt T G. A novel approach of combined high resolution T2-w and parametrically analyzed dynamic contrast enhanced T1-w MR imaging for radiation treatment planning of the prostate. Strahlentherapie und Onkologie 2006; 182: 78S
   Google Scholar
• Schmuecking M, Baum R P, Bonnet R, Junker K, Mueller K M. Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 2005; 26: 178–189
   PubMed Web of Science ®Google Scholar
• Shukla-Dave A, Hricak H, Eberhardt S C, Olgac S, Muruganandham M, Scardino P T, Reuter V E, Koutcher J A, Zakian K L. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings – initial observations. Radiology 2004; 231: 717–724
   PubMed Web of Science ®Google Scholar
• Symon Z, Griffith K A, McLaughlin P W, Sullivan M, Sandler H M. Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. International Journal of Radiation Oncology Biology Physics 2003; 57: 384–390
   PubMed Web of Science ®Google Scholar
• Tanderup K, Olsen D R, Grau C. Dose painting: Art or science. Radiotherapy and Oncology 2006; 79: 245–248
   PubMed Web of Science ®Google Scholar
• Tofts P S, Brix G, Buckley D L, Evelhoch J L, Henderson E, Knopp M V, Larsson H B, Lee T Y, Mayr N A, Parker G J, Port R E, Taylor J, Weisskoff R M. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging 1999; 10: 223–232
   PubMed Web of Science ®Google Scholar
• Tofts P S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. Journal of Magnetic Resonance Imaging 1997; 7: 91–101
   PubMed Web of Science ®Google Scholar
• Villeirs G M, Verstraete K L, De Neve W J, De Meerleer G O. Magnetic resonance imaging anatomy of the prostate and periprostatic area: A guide for radiotherapists. Radiotherapy and Oncology 2005a; 76: 99–106
   PubMed Web of Science ®Google Scholar
• Villeirs G M, Van Vaerenbergh K, Vakaet L, Bral S, Claus F, De Neve W J, Verstraete K L, De Meerleer G O. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlentherapie und Onkologie 2005b; 181: 424–430
   PubMed Web of Science ®Google Scholar
• Wang L, Hricak H, Kattan M W, Chen H N, Scardino P T, Kuroiwa K. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238: 597–603
   PubMed Web of Science ®Google Scholar
• Wefer A E, Hricak H, Vigneron D B, Coakley F V, Lu Y, Wefer J, Mueller-Lisse U, Carroll P R, Kurhanewicz J. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. Journal of Urology 2000; 164: 400–404
   PubMed Web of Science ®Google Scholar
• Wu X, Dibiase S J, Gullapalli R, Yu X C. Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning. International Journal of Radiation Oncology Biology Physics 2004; 58: 1577–1583
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, Shizukuishi K, Endou H, Kubota Y, Inoue T. Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32: 742–748
   PubMed Web of Science ®Google Scholar
• Yu K K, Scheidler J, Hricak H, Vigneron D B, Zaloudek C J, Males R G, Nelson S J, Carroll P R, Kurhanewicz J. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213: 481–488
   PubMed Web of Science ®Google Scholar
• Zelefsky M J, Fuks Z, Hunt M, Yamada Y, Marion C, Ling C C, Amols H, Venkatraman E S, Leibel S A. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology Biology Physics 2002; 53: 1111–1116
   PubMed Web of Science ®Google Scholar
• Zelefsky M J, Fuks Z, Hunt M, Lee H J, Lombardi D, Ling C C, Reuter V E, Venkatraman E S, Leibel S A. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Journal of Urology 2001; 166: 876–881
   PubMed Web of Science ®Google Scholar
• Zhao D, Jiang L, Hahn E W, Mason R P. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. International Journal of Radiation Oncology Biology Physics 2005; 62: 872–880
   PubMed Web of Science ®Google Scholar
• Zaider M, Zelefsky M J, Lee E K, Zakian K L, Amols H I, Dyke J, Cohen G, Hu Y, Endi A K, Chui C, Koutcher J A. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. International Journal of Radiation Oncology Biology Physics 2000; 47: 1085–1096
   PubMed Web of Science ®Google Scholar